Literature DB >> 23467619

Oxaliplatin-induced lung injury with allergic reaction.

Tetsuya Homma1, Masatsugu Kurokawa, Yoshitaka Yamamoto, Satoshi Matsukura, Koushi Ieki, Shintaro Suzuki, Miho Odaka, Shin Watanabe, Munehiro Yamaguchi, Mitsuru Adachi.   

Abstract

A 79-year-old man was diagnosed as stage IV colon cancer and treated with a modified FOLFOX6 (mFOLFOX6) regimen. On the 12th cycle, we observed erythema and dyspnea. Radiographs showed ground grass opacities. Blood tests showed elevated levels of eosinophils and immunoglobulin E. We diagnosed this finding as response to drug allergy and administered high-dose methylprednisolone. The treatment was successful and he was discharged. The drug lymphocyte stimulating test against oxaliplatin was positive, indicating a type I and IV allergic reaction due to oxaliplatin. Regimens including oxaliplatin must be carefully monitored and frequent blood tests and chest radiographs are needed.

Entities:  

Keywords:  Drug lymphocyte stimulating test; Drug-induced pneumonia; Immunoglobulin E; Oxaliplatin; mFOLFOX6

Year:  2011        PMID: 23467619      PMCID: PMC3587561          DOI: 10.1007/s11670-011-0232-y

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  27 in total

1.  Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.

Authors:  R Trisolini; L Lazzari Agli; D Tassinari; D Rondelli; A Cancellieri; M Patelli; F Falcone; V Poletti
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

2.  Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.

Authors:  Xavier Hernández Yagüe; Ester Soy; Bernardo Queralt Merino; Josep Puig; Miguel Beltrán Fabregat; Ramón Colomer
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 4.  Clinical toxicities encountered with paclitaxel (Taxol).

Authors:  E K Rowinsky; E A Eisenhauer; V Chaudhry; S G Arbuck; R C Donehower
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

5.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

6.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

7.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Authors:  L Rubbia-Brandt; V Audard; P Sartoretti; A D Roth; C Brezault; M Le Charpentier; B Dousset; P Morel; O Soubrane; S Chaussade; G Mentha; B Terris
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

8.  Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage.

Authors:  U Costabel; H Teschler; J Guzman
Journal:  Eur Respir J       Date:  1992-07       Impact factor: 16.671

9.  Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.

Authors:  Frederic Gagnadoux; Cecile Roiron; Emmanuelle Carrie; Laurence Monnier-Cholley; Bernard Lebeau
Journal:  Am J Clin Oncol       Date:  2002-08       Impact factor: 2.339

Review 10.  Diagnosis and management of drug-associated interstitial lung disease.

Authors:  N L Müller; D A White; H Jiang; A Gemma
Journal:  Br J Cancer       Date:  2004-08       Impact factor: 7.640

View more
  2 in total

1.  Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report.

Authors:  Wai Cheong Soon; Kate West; David Gibeon; Elizabeth Frances Bowen
Journal:  Case Rep Oncol       Date:  2014-09-24

Review 2.  Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient.

Authors:  Annick De Weerdt; Amélie Dendooven; Annemie Snoeckx; Jan Pen; Martin Lammens; Philippe G Jorens
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.